JGJustin Goodwin

Justin Goodwin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Justin Goodwin has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial

    by Meghan E. Whalen, Richard Kajubi, Justin Goodwin, Francis Orukan, McKenzie Colt, Liusheng Huang, Kacey Richards, Thomas J. Hoffmann, Francesca T. Aweeka, Sunil Parikh, et al.

    Malaria and HIV co‐infection are prevalent in sub‐Saharan Africa causing significant drug interactions with co‐treatment. We previously reported a 30%‐70% reduction in exposure to the standard 3‐day (6‐dose) artemether‐lumefantrine (AL) treatment for malaria when given with efavirenz‐based HIV therapy, impacting malaria reinfection risk. We conducted a prospective, randomized study comparing the 3‐day regimen to an extended 5‐day (10‐dose) regimen with pharmacokinetic sampling for artemether, dihydroartemisinin, lumefantrine, and desbutyl‐lumefantrine (DBL) over 42 days. The primary outcome was comparative pharmacokinetics between regimens compared among children with HIV and among children without HIV receiving a 3‐day regimen as controls (median age 5.3 years [range 1.4‐13.9]; median weight 17.3 kg [range 8.7‐39.1]). Children with HIV (n = 57; median age 10.8 years [range 3.4‐17.1]; median weight 26.6 kg [range 14.6‐54.5]) contributed 76 malaria episodes, with 71 included in the analysis. Another 97 children without HIV (median age 5.3 years [range 1.4‐13.9]; median weight 17.3 kg [range 8.7‐39.1]) contributed 114 episodes of malaria, with 109 included in the analysis. In the setting of efavirenz, artemether, dihydroartemisinin, lumefantrine, and DBL cumulative exposure was 2.09, 2.31, 1.90, and 1.65 fold higher with 5‐day versus 3‐day AL (all P < .001), and comparable to 3‐day AL in children without HIV. The extended regimen in children with HIV did not result in a statistically significant reduction in recurrence risk at 28 or 42 days. Extending the duration of AL to 5 days compensated for a clinically significant reduction in all components of AL in the context of EFV‐based antiretroviral therapy in young children.


  • Open Access

    Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children

    by Justin Goodwin, Richard Kajubi, Kaicheng Wang, Fangyong Li, Martina Wade, Francis Orukan, Liusheng Huang, Meghan Whalen, Francesca T. Aweeka, Norah Mwebaza, et al.

    Standard diagnostics used in longitudinal antimalarial studies are unable to characterize the complexity of submicroscopic parasite dynamics, particularly in high transmission settings. We use molecular markers and amplicon sequencing to characterize post-treatment stage-specific malaria parasite dynamics during a 42 day randomized trial of 3- versus 5 day artemether-lumefantrine in 303 children with and without HIV (ClinicalTrials.gov number NCT03453840). The prevalence of parasite-derived 18S rRNA is >70% in children throughout follow-up, and the ring-stage marker SBP1 is detectable in over 15% of children on day 14 despite effective treatment. We find that the extended regimen significantly lowers the risk of recurrent ring-stage parasitemia compared to the standard 3 day regimen, and that higher day 7 lumefantrine concentrations decrease the probability of ring-stage parasites in the early post-treatment period. Longitudinal amplicon sequencing reveals remarkably dynamic patterns of multiclonal infections that include new and persistent clones in both the early post-treatment and later time periods. Our data indicate that post-treatment parasite dynamics are highly complex despite efficacious therapy, findings that will inform strategies to optimize regimens in the face of emerging partial artemisinin resistance in Africa.


  • Open Access

    Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda

    by Katherine Kay, Justin Goodwin, Hanna Ehrlich, Joyce Ou, Tracey Freeman, Kaicheng Wang, Fangyong Li, Martina Wade, Jonathan French, Liusheng Huang, et al.

    Artemisinin‐based combination therapies (ACTs) are the primary treatment for malaria. It is essential to characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of ACTs in vulnerable populations at risk of suboptimal dosing. We developed a population PK/PD model using data from our previous study of artemether‐lumefantrine in HIV‐uninfected and HIV‐infected children living in a high‐transmission region of Uganda. HIV‐infected children were on efavirenz‐, nevirapine‐, or lopinavir‐ritonavir‐based antiretroviral regimens, with daily trimethoprim‐sulfamethoxazole prophylaxis. We assessed selection for resistance in two key parasite transporters, pfcrt and pfmdr1, over 42‐day follow‐up and incorporated genotyping into a time‐to‐event model to ascertain how resistance genotype in relation to drug exposure impacts recurrence risk. Two hundred seventy‐seven children contributed 364 episodes to the model (186 HIV‐uninfected and 178 HIV‐infected), with recurrent microscopy‐detectable parasitemia detected in 176 episodes by day 42. The final model was a two‐compartment model with first‐order absorption and an estimated age effect on bioavailability. Systemic lumefantrine exposure was highest with lopinavir‐ritonavir, lowest with efavirenz, and equivalent with nevirapine and HIV‐uninfected children. HIV status and lumefantrine concentration were significant factors associated with recurrence risk. Significant selection was demonstrated for pfmdr1 N86 and pfcrt K76 in recurrent infections, with no evidence of selection for pfmdr1 Y184F. Less sensitive parasites were able to tolerate lumefantrine concentrations ~ 3.5‐fold higher than more sensitive parasites. This is the first population PK model of lumefantrine in HIV‐infected children and demonstrates selection for reduced lumefantrine susceptibility, a concern as we confront the threat to ACTs posed by emerging artemisinin resistance in Africa.


  • Open Access

    Identification of novel genetic variants in the malaria vaccine candidate PfRh5: structure-guided insights into potential function

    by Khadidiatou Mangou, Adam J. Moore, Laty Gaye Thiam, Aboubacar Ba, Alessandra Orfanó, Ife Desamours, Duncan Ndungu Ndegwa, Justin Goodwin, Yicheng Guo, Zizhang Sheng, et al.

    The recent stall in the global reduction of malaria deaths has made the development of a highly effective vaccine essential. A major challenge to developing an efficacious vaccine is the extensive diversity of Plasmodium falciparum antigens. While genetic diversity plays a major role in immune evasion and is a barrier to the development of both natural and vaccine-induced protective immunity, it has been under-prioritized in the evaluation of malaria vaccine candidates. This study uses genomic approaches to evaluate genetic diversity in next generation malaria vaccine candidate PfRh5. We used targeted deep amplicon sequencing to identify non-synonymous Single Nucleotide Polymorphisms (SNPs) in PfRH5 (Reticulocyte-Binding Protein Homologue 5) in 189 P. falciparum positive samples from Southern Senegal and identified 74 novel SNPs. We evaluated the population prevalence of these SNPs as well as the frequency in individual samples and found that only a single SNP, C203Y, was present at every site. Many SNPs were unique to the individual sampled, with over 90% of SNPs being found in just one infected individual. In addition to population prevalence, we assessed individual level SNP frequencies which revealed that some SNPs were dominant (frequency of greater than 25% in a polygenomic sample) whereas most were rare, present at 2% or less of total reads mapped to the reference at the given position. Structural modeling uncovered 3 novel SNPs occurring under epitopes bound by inhibitory monoclonal antibodies, potentially impacting immune evasion, while other SNPs were predicted to impact PfRh5 structure or interactions with the receptor or binding partners. Our data demonstrate that PfRh5 exhibits greater genetic diversity than previously described, with the caveat that most of the uncovered SNPs are at a low overall frequency in the individual and prevalence in the population. The structural studies reveal that novel SNPs could have functional implications on PfRh5 receptor binding, complex formation, or immune evasion, supporting continued efforts to validate PfRh5 as an effective malaria vaccine target and development of a PfRh5 vaccine.

  • Open Access

    Implementation of a volunteer contact tracing program for COVID-19 in the United States: A qualitative focus group study

    by Tyler Shelby, Rachel Hennein, Christopher Schenck, Katie Clark, Amanda J Meyer, Justin Goodwin, Brian Weeks, Maritza Bond, Linda Niccolai, J Lucian Davis, et al.

    Background: Contact tracing is an important tool for suppressing COVID-19 but has been difficult to adapt to the conditions of a public health emergency. This study explored the experiences and perspectives of volunteer contact tracers in order to identify facilitators, challenges, and novel solutions for implementing COVID-19 contact tracing.Methods: As part of a study to evaluate an emergently established volunteer contact tracing program for COVID-19 in New Haven, Connecticut, April-June 2020, we conducted focus groups with 36 volunteer contact tracers, thematically analyzed the data, and synthesized the findings using the RE-AIM implementation framework.Results: To successfullyreachcases and contacts, participants recommended identifying clients’ outreach preferences, engaging clients authentically, and addressing sources of mistrust. Participants felt that theeffectivenessof successful isolation and quarantine was contingent on minimizing delays in reaching clients and on systematically assessing and addressing their nutritional, financial, and housing needs. They felt that successfuladoptionof a volunteer-driven contact tracing model depended on the ability to recruit self-motivated contact tracers and provide rapid training and consistent, supportive supervision. Participants noted thatimplementationcould be enhanced with better management tools, such as more engaging interview scripts, user-friendly data management software, and protocols for special situations and populations. They also emphasized the value of coordinating outreach efforts with other involved providers and agencies. Finally, they believed that long-termmaintenanceof a volunteer-driven program requires monetary or educational incentives to sustain participation.Conclusions: This is one of the first studies to qualitatively examine implementation of a volunteer-run COVID-19 contact tracing program. Participants identified facilitators, barriers, and potential solutions for improving implementation of COVID-19 contact tracing in this context. These included standardized communication skills training, supportive supervision, and peer networking to improve implementation, as well as greater cooperation with outside agencies, flexible scheduling, and volunteer incentives to promote sustainability.


  • Open Access

    p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas

    by Meng-Hsiung Hsieh, Joshua H. Choe, Jashkaran Gadhvi, Yoon Jung Kim, Marcus A. Arguez, Madison Palmer, Haleigh Gerold, Chance Nowak, Hung Do, Simbarashe Mazambani, et al.


  • Glucose Transporter 1 Gene Variants Predict the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer

    by Sook Kyung Do, Ji Yun Jeong, Shin Yup Lee, Jin Eun Choi, Mi Jeong Hong, Hyo-Gyoung Kang, Won Kee Lee, Yangki Seok, Eung Bae Lee, Kyung Min Shin, et al.

    This study was conducted to investigate whether polymorphisms of glucose transporter 1 (GLUT1) gene are associated with the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection.


  • Targeting Hypoxia-Inducible Factor-1α/Pyruvate Dehydrogenase Kinase 1 Axis by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis

    by Justin Goodwin, Hyunsung Choi, Meng-Hsiung Hsieh, Michael L. Neugent, Jung-Mo Ahn, Heather N. Hayenga, Pankaj K. Singh, David B. Shackelford, In-Kyu Lee, Vladimir Shulaev, et al.

    Hypoxia has long been implicated in the pathogenesis of fibrotic diseases. Aberrantly activated myofibroblasts are the primary pathological driver of fibrotic progression, yet how various microenvironmental influences, such as hypoxia, contribute to their sustained activation and differentiation is poorly understood. As a defining feature of hypoxia is its impact on cellular metabolism, we sought to investigate how hypoxia-induced metabolic reprogramming affects myofibroblast differentiation and fibrotic progression, and to test the preclinical efficacy of targeting glycolytic metabolism for the treatment of pulmonary fibrosis. Bleomycin-induced pulmonary fibrotic progression was evaluated in two independent, fibroblast-specific, promoter-driven, hypoxia-inducible factor (Hif) 1A knockout mouse models and in glycolytic inhibitor, dichloroacetate-treated mice. Genetic and pharmacological approaches were used to explicate the role of metabolic reprogramming in myofibroblast differentiation. Hypoxia significantly enhanced transforming growth factor-β–induced myofibroblast differentiation through HIF-1α, whereas overexpression of the critical HIF-1α–mediated glycolytic switch, pyruvate dehydrogenase kinase 1 (PDK1) was sufficient to activate glycolysis and potentiate myofibroblast differentiation, even in the absence of HIF-1α. Inhibition of the HIF-1α/PDK1 axis by genomic deletion of Hif1A or pharmacological inhibition of PDK1 significantly attenuated bleomycin-induced pulmonary fibrosis. Our findings suggest that HIF-1α/PDK1–mediated glycolytic reprogramming is a critical metabolic alteration that acts to promote myofibroblast differentiation and fibrotic progression, and demonstrate that targeting glycolytic metabolism may prove to be a potential therapeutic strategy for the treatment of pulmonary fibrosis.


  • Open Access

    A New Perspective on the Heterogeneity of Cancer Glycolysis

    by Michael L. Neugent, Justin Goodwin, Ishwarya Sankaranarayanan, Celal Emre Yetkin, Meng-Hsiung Hsieh, Jung-Whan Kim

    Tumors are dynamic metabolic systems which highly augmented metabolic fluxes and nutrient needs to support cellular proliferation and physiological function. For many years, a central hallmark of tumor metabolism has emphasized a uniformly elevated aerobic glycolysis as a critical feature of tumorigenecity. This led to extensive efforts of targeting glycolysis in human cancers. However, clinical attempts to target glycolysis and glucose metabolism have proven to be challenging. Recent advancements revealing a high degree of metabolic heterogeneity and plasticity embedded among various human cancers may paint a new picture of metabolic targeting for cancer therapies with a renewed interest in glucose metabolism. In this review, we will discuss diverse oncogenic and molecular alterations that drive distinct and heterogeneous glucose metabolism in cancers. We will also discuss a new perspective on how aberrantly altered glycolysis in response to oncogenic signaling is further influenced and remodeled by dynamic metabolic interaction with surrounding tumor-associated stromal cells.


  • Open Access

    Lung squamous cell carcinoma exhibits a targetable glucose dependency unique among non-small cell lung cancers

    by Justin Goodwin, Michael L. Neugent, Jung-Whan Kim

    Cancer cells consume high amounts of glucose for their cellular bioenergetic and anabolic requirements, relying on glucose to fuel their growth. We recently reported that lung squamous cell carcinoma, a major subtype of non-small cell lung cancer (NSCLC), exhibits remarkably elevated glucose transporter GLUT1 (encoded by SLC2A1) expression and glucose dependency, while another subtype of NSCLC, lung adenocarcinoma, shows significant glucose independence. Our findings highlight the metabolic heterogeneity of glucose metabolism among lung cancer subtypes, which can be exploited for targeted lung cancer therapies.